Journal of Current and Advance Medical Research
January 2025, Vol. 12, No. 1, pp. 3-9
http://www.banglajol.info/index.php/JCAMR
ISSN (Print) 2313-447X
ISSN (Online) 2413-323X
NLM Catalog ID 101673828
DOI: https://doi.org/10.3329/jcamr.v12i1.90987

Original Article

Impact of Nano-Biotechnology on Personalized Healthcare

Mohammed Shawket Bairmani[1], Haneen Saleem Al-Araji[2]

[1]Lecturer, Department of Applied Biotechnology, College of Biotechnology, Al-Qasim Green University, Babylon, Iraq; [2]MSc. Fellow, Department of Medical Biotechnology, College of Biotechnology, Al-Qasim Green University, Babylon, Iraq

The health care system has been rapidly developed in the last decades to discourse the growing realization that individual patients often respond differently to the same therapeutic interventions and that traditional approaches to the practice of medicine have limitations and more personalized strategies are needed. Precision medicine is a paradigm shift in the approach to illness prevention, diagnosis, and treatment that aims to customize care for every individual based on the unique genetic, biochemical, environmental, and lifestyle factors that characterize that individual. In this developing environment, Nanobiotechnology has become one of the most promising enabling technologies, providing revolutionary tools that can improve the accuracy, efficiency and efficacy of customized healthcare. Nanotechnology deals with materials on the nanometer scale between 1 and 100 nanometers and offers unparalleled possibilities to interact with biological systems in very particular and regulated manners.

Nanotechnology and precision medicine are coming together to revolutionize current healthcare, encompassing targeted medication delivery, increased diagnostic sensitivity, real-time illness monitoring and the creation of personalized treatment interventions. The most significant contribution of nanotechnology to precision medicine is in targeted medication delivery. Where size depends properties is the key issue that nanotechnology relaying on. Traditional medication delivery typically results in dissemination of therapeutic agents throughout the body exposing healthy tissues to unnecessary drug concentrations and raising the potential of unwanted consequences. This constraint can be solved by smart delivery of the therapeutic molecule using nano carrier and delivery systems that selectively distribute medications to specific tissues, organs or cellular targets. Surface modifications and functionalization with antibodies, peptides or ligands enable the nanoparticles to identify and bind to various biomarkers, thereby assuring that therapeutic chemicals aggregate predominantly at the targeted site of action. This results in better patient outcomes and quality of life, more treatment efficiency and lower systemic toxicity. Such benefits have been especially remarkable in the field of oncology, in which nanocarriers have exhibited the potential to carry chemotherapeutic drugs to malignant tissues without attacking healthy cells.

Nanotechnology is transforming the face of diagnostic medicine through the creation of extremely sensitive and selective detection systems, in addition to its therapeutic application. Early diagnosis remains one of the most important variables determining the prognosis of illnesses, especially in diseases such as cancer, cardiovascular problems and infectious diseases. Because of the unique optical, magnetic, electrical and chemical characteristics of nanomaterials, they are suitable candidates for enhanced biosensing technologies to enhance specific diagnosing method. Nanobiosensors can typically detect very low levels of disease related biomarkers in blood, urine, saliva and other biological materials before clinical symptoms appear. This leads to early intervention, better cure rates and lower cost of care for advanced disease. Additionally, the application of nanotechnology with imaging agents has dramatically improved the resolution and sensitivity of diagnostic imaging techniques including magnetic resonance imaging, computed tomography, positron emission tomograph and fluorescence imaging, providing clinicians with

more precise data on disease location, advancement, and response to treatment.

Theranostic nanoparticles can simultaneously detect illness, provide medication and assess therapeutic responses in real time, giving doctors dynamic information to guide tailored treatment modifications. This integration fits well with the aims of precision medicine by enabling continuous evaluation of patient specific responses and evidence-based adjustments of therapy regimens. Theranostic systems are of special interest in the management of cancer, where treatment resistance tumor heterogeneity and disease recurrence can challenge clinical decision making. Nanotechnology offers the promise of both diagnostic and therapeutic capabilities that can assist to address many of these difficulties and lead to more flexible and successful treatment techniques. Nanotechnology has also played an important expanding role in personalized healthcare through its integration due to the innovation properties that nanotechnology brought, with genomic and molecular medicine. Next generation sequencing, proteomics, metabolomics and bioinformatics have created large volumes of biological data that may be utilized to find patient specific disease processes and treatment targets. Nanotechnology gives us the means to transform these molecular discoveries into actual therapeutic applications. Nanoparticles are constructed to transport genetic material including DNA, messenger RNA, small interfering RNA, and gene editing machinery into target cells for precise regulation of gene expression. The extraordinary success of messenger RNA vaccines delivered by lipid nanoparticles has proven the therapeutic promise of nanotechnology in the safe and efficient delivery of complex biological molecules. This breakthrough has covered the way for the creation of individualized vaccinations, gene treatments and immunotherapies that target the distinctive features of individual patients.

Nanotoxicity on the other hand is one of the major issues which need to be solv. The same physicochemical features that make nanoparticles interesting for medicinal applications may also affect their interactions with biological systems in unforeseen ways. Particle size, shape, surface charge, content and biodegradability can influence bio distribution, cellular absorption, immunological responses and possible toxicity. Thus, an extensive safety evaluation is necessary for the validation of therapeutic benefit from the use of nanomedicine products without adverse side effects. Regulatory difficulties remain a key hurdle. Current regulatory systems were mostly built for traditional medicines and medical equipment and might not be appropriate for the intricacies of nanotechnology-based goods. Lack of consistent evaluation methodologies, characterization protocols and worldwide criteria might hinder product approval processes and delay clinical translation. Furthermore, manufacturing and scalability concerns continue to be serious challenges. The manufacturing of nanoparticles on industrial scale with consistent quality, stability and reproducibility demands advanced technology and strict quality control systems which can lead to increasing production costs. Access may consequently be limited by economic considerations, particularly in low- and middle-income nations with scarce healthcare resources.

[Journal of Current and Advance Medical Research, January 2025;12(1):1-2]

Correspondence: Dr. Mohammed Shawket Bairmani, Lecturer, Department of Applied Biotechnology, College of Biotechnology, Al-Qasim Green University, Babylon 51013, Iraq; **Cell no**.: +9647828113306; **Email**: mshbiotech86@gmail.com; **ORCID**: https://orcid.org/0009-0009-0072-8230